INmune Bio Reports New Phase 2 Grey Matter Imaging Data at CTAD Conference Reinforcing XPro1595’s Evidence Base in High-Inflammation Alzheimer's Patients

Core Insights - INmune Bio, Inc. announced new neuroimaging data from its Phase 2 MINDFuL trial of XPro1595 in early Alzheimer's disease patients with elevated neuroinflammation, to be presented at the 18th Clinical Trials on Alzheimer's Disease conference [1][2] Group 1: Clinical Trial Results - The new analyses support XPro1595's mechanism of selectively neutralizing soluble TNF (sTNF), validating the strategy of targeting inflammation-driven Alzheimer's disease, which represents a significant unmet need [2][9] - PerpPD+ MRI imaging analysis indicated a trend towards slowed neurodegeneration progression in patients receiving XPro1595, particularly in those with early Alzheimer's and high inflammatory burden [3][8] - Findings suggest reduced cortical disarray, an imaging hallmark of neurodegeneration, reinforcing previously reported improvements across biological, cognitive, and neuropsychiatric endpoints [4][5] Group 2: Future Developments - Additional MRI analyses from the MINDFuL trial are ongoing and will provide a broader understanding of XPro1595's impact on gray- and white-matter integrity in Alzheimer's patients [7] - The totality of data generated to date positions XPro1595 as a promising first-in-class disease-modifying therapy for Alzheimer's patients with elevated neuroinflammation, a population with limited treatment options [9][10] Group 3: Company Overview - INmune Bio Inc. is a clinical-stage biotechnology company focused on developing treatments targeting innate immune dysfunction to combat diseases [11] - The company's pipeline includes XPro1595, an inhibitor of soluble TNF that aims to restore healthy innate immune function without the immunosuppressive effects of traditional TNF inhibitors [10]